Insights

Acquisition by Pfizer Global Blood Therapeutics was acquired by Pfizer, a leading pharmaceutical company, for $5.4 billion. This acquisition opens up potential synergies and sales opportunities within Pfizer's existing network and customer base.

Phase 3 Clinical Trials GBT launched the Phase 3 HOPE-KIDS 2 study for sickle cell disease treatment, indicating an advanced stage in product development. Engaging with healthcare providers involved in this trial presents sales opportunities for future partnerships or product adoption.

Developing Next-Gen Treatments GBT is actively working on developing the next generation of treatments for sickle cell disease. Exploring collaborations with GBT's drug discovery teams can lead to potential sales opportunities for innovative products in the pipeline.

Focused on ESG GBT launched its inaugural environmental, social, and governance (ESG) report, showcasing a commitment to sustainable value creation. Partnering with companies aligned with ESG principles can create sales opportunities based on shared values and initiatives.

New CEO Appointment Dr. Love was appointed as CEO of GBT, bringing industry experience and leadership to the company. Leveraging relationships or partnerships established by the new CEO can lead to sales opportunities through strategic collaborations and introductions.

Global Blood Therapeutics Tech Stack

Global Blood Therapeutics uses 8 technology products and services including Google Analytics, React, Backbone.js, and more. Explore Global Blood Therapeutics's tech stack below.

  • Google Analytics
    Analytics
  • React
    Javascript Frameworks
  • Backbone.js
    Javascript Frameworks
  • Yoast SEO
    Search Engines
  • Akamai Bot Manager
    Security
  • Google Tag Manager
    Tag Management
  • Adobe Tag Manager
    Tag Management
  • Drupal Multisite
    Web Hosting

Media & News

Global Blood Therapeutics's Email Address Formats

Global Blood Therapeutics uses at least 2 format(s):
Global Blood Therapeutics Email FormatsExamplePercentage
flast@gbt.comJDoe@gbt.com
93%
last@gbt.comDoe@gbt.com
3%
firstl@gbt.comJohnD@gbt.com
3%
fl@gbt.comJD@gbt.com
1%
flast@globalbloodtx.comJDoe@globalbloodtx.com
86%
first.last@globalbloodtx.comJohn.Doe@globalbloodtx.com
9%
lastfirst@globalbloodtx.comDoeJohn@globalbloodtx.com
2%
lfirst@globalbloodtx.comDJohn@globalbloodtx.com
2%
last@globalbloodtx.comDoe@globalbloodtx.com
0%
f.last@globalbloodtx.comJ.Doe@globalbloodtx.com
1%

Frequently Asked Questions

Where is Global Blood Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Global Blood Therapeutics's main headquarters is located at 181 Oyster Point Blvd South San Francisco, California 94080 US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is Global Blood Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Global Blood Therapeutics's main corporate office by phone at +1-650-741-7700. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Global Blood Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Global Blood Therapeutics is a publicly traded company; the company's stock symbol is GBT.

What is Global Blood Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Global Blood Therapeutics's official website is gbt.com and has social profiles on LinkedIn.

How much revenue does Global Blood Therapeutics generate?

Minus sign iconPlus sign icon
As of April 2024, Global Blood Therapeutics's annual revenue reached $75M.

What is Global Blood Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Global Blood Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Global Blood Therapeutics have currently?

Minus sign iconPlus sign icon
As of April 2024, Global Blood Therapeutics has approximately 124 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: J. K.Chief Executive Officer: J. H.Chief Executive Officer: B. M.. Explore Global Blood Therapeutics's employee directory with LeadIQ.

What industry does Global Blood Therapeutics belong to?

Minus sign iconPlus sign icon
Global Blood Therapeutics operates in the Biotechnology Research industry.

What technology does Global Blood Therapeutics use?

Minus sign iconPlus sign icon
Global Blood Therapeutics's tech stack includes Google AnalyticsReactBackbone.jsYoast SEOAkamai Bot ManagerGoogle Tag ManagerAdobe Tag ManagerDrupal Multisite.

What is Global Blood Therapeutics's email format?

Minus sign iconPlus sign icon
Global Blood Therapeutics's email format typically follows the pattern of . Find more Global Blood Therapeutics email formats with LeadIQ.

How much funding has Global Blood Therapeutics raised to date?

Minus sign iconPlus sign icon
As of April 2024, Global Blood Therapeutics has raised $300M in funding. The last funding round occurred on Dec 15, 2021.

When was Global Blood Therapeutics founded?

Minus sign iconPlus sign icon
Global Blood Therapeutics was founded in 2011.
Global Blood Therapeutics

Global Blood Therapeutics

Biotechnology ResearchCalifornia, United States201-500 Employees

Global Blood Therapeutics (GBT) is now part of Pfizer, and we look forward to continuing our mission on behalf of people living with sickle cell disease. The Global Blood Therapeutics page will no longer be active or monitored. Please follow Pfizer for new content.

Section iconCompany Overview

Headquarters
181 Oyster Point Blvd South San Francisco, California 94080 US
Phone number
+1-650-741-7700
Website
gbt.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
GBT
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2011
Employees
201-500

Section iconFunding & Financials

  • $300M

    Global Blood Therapeutics has raised a total of $300M of funding over 7 rounds. Their latest funding round was raised on Dec 15, 2021.

  • $50M$100M

    Global Blood Therapeutics's revenue is in the range of $50M$100M

Section iconFunding & Financials

  • $300M

    Global Blood Therapeutics has raised a total of $300M of funding over 7 rounds. Their latest funding round was raised on Dec 15, 2021.

  • $50M$100M

    Global Blood Therapeutics's revenue is in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.